Disc Medicine has achieved a critical milestone in its quest to bring a new therapy for erythropoietic protoporphyria (EPP) to patients. On September 29, 2025, the company submitted an NDA for bitopertin and secured the FDA Commissioner’s National Priority Voucher, a move that could significantly accelerate the drug’s review and potential approval.